MedPath

Does Continuous Vital Sign Monitoring Increase Investigations and Interventions in Complication-free Patients?

Not Applicable
Completed
Conditions
Surgery-Complications
Chronic Obstructive Pulmonary Disease
Cancer
Interventions
Device: Active alarms from WARD software
Registration Number
NCT06361862
Lead Sponsor
Rigshospitalet, Denmark
Brief Summary

This aim of this study is to investigate whether active alerts during CVSM result in an increased number of diagnostic tests and treatments in complication free patients, hypothesizing that more interventions are performed in the CVSM-group than standard of care (EWS) group.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
700
Inclusion Criteria
  • • Patients from WARD - RCT.
Exclusion Criteria

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
active alarmsActive alarms from WARD softwarePatients with continuous monitoring with active alerts from WARD.
Primary Outcome Measures
NameTimeMethod
Frequency of patients having at least one of the following tests/treatments:72 hours

* CT-scans

* MRi-Scans

* PET-Scans

* X-ray (ordered by attending doctor, besides standard procedural investigations)

* ultrasounds

* Antibiotics (ordered by attending doctor, besides standard procedural treatment)

* Arterial puncture

* Gastro- colonoscopy

* Dialysis

* Central venous line (incl. dialysis catheter)

Secondary Outcome Measures
NameTimeMethod
The frequency of individual treatments and diagnostics:72 hours

Treatments:

* Antibiotics (ordered by attending doctor, besides standard procedural treatment)

* CPAP

* blood-transfusion

* IV-fluids

* Dialysis

* Naso-gastric tube (ordered by attending doctor, besides standard procedural treatment)

* Central venous line (incl. dialysis catheter)

Diagnostics:

* Imaging CT, X-ray, MRI, PET, and ultrasound.

* Blood tests: arterial blood gases, cultures, and other blood sample tests.

* ECG

* cultures from urine, sputum, swabs, and feces.

Trial Locations

Locations (1)

Eske Kvanner Aasvang

🇩🇰

Copenhagen, Denmark

© Copyright 2025. All Rights Reserved by MedPath